Delivery Order SPE2DB24D2010-SPE2DB25FZUR8

Award Date 1/22/25
Potential Completion Date 1/23/25
Potential Value $1.4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The federal contract award is for the delivery of XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML pharmaceutical products to the Defense Logistics Agency (DLA), a defense agency. The contract, valued at $1,575.18, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on November 4, 2024. The contract has a completion date of November 5, 2024 and is a firm fixed-price delivery order. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award is for the delivery of XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML pharmaceutical products to the U.S. Department of Defense's Medical Supply Chain agency. The $1,607.18 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on July 23, 2024, with a completion date of July 24, 2024. This order is a part of Amerisourcebergen's broader Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop...
The federal contract award is for the delivery of XYOSTED 75 MG/0.5 ML AUTO-INJ 0.5ML pharmaceutical products. The contract, valued at $1,428.02, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA), a defense agency. The contract is a delivery order with a firm fixed price and has an ultimate completion date of June 18, 2025. AmerisourceBergen Drug Corp is a significant vendor for the DLA, holding...
The federal contract award is for the delivery of XYOSTED 75 MG/0.5 ML AUTO-INJ 0.5ML pharmaceutical products. The contract, valued at $1,420.61, was awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order with a firm fixed price and an ultimate completion date of July 18, 2025. The place of performance is Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp holds a...
This federal contract award is for the delivery of XYOSTED 75 MG/0.5 ML AUTO-INJ 0.5ML pharmaceutical products to the Defense Logistics Agency (DLA). The $1,111.33 firm fixed price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on August 15, 2024, with an ultimate completion date of August 16, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999, for the supply of a...
This federal contract award is for the delivery of XYOSTED 50 MG/0.5 ML AUTO-INJ 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract, valued at $1,344.65, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order with a Firm Fixed Price pricing type, and has an ultimate completion date of October 23, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract...
This federal contract award is for the delivery of XYOSTED 50 MG/0.5 ML AUTO-INJ 0.5ML pharmaceutical products. The contract, valued at $2,379.57, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA), a defense agency. The contract is a Firm Fixed Price Delivery Order with a performance period ending on July 14, 2025. It is not designated as a set-aside contract, indicating open competition....
This federal contract award is for the delivery of XYOSTED 75 MG/0.5 ML AUTO-INJ 0.5ML pharmaceutical products to the Defense Logistics Agency (DLA). The $1,511.04 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on October 28, 2024 with a completion date of October 29, 2024. The contract is not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML, a pharmaceutical product, with a ceiling value of $1,377.33. The contract is a Firm Fixed Price Delivery Order with a period of performance through July 3, 2025. This award is not associated with a set-aside designation, indicating open...
This federal contract award is for the delivery of XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML pharmaceutical products. The contract, valued at $1,239.03, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract is a Firm Fixed Price Delivery Order with a completion date of October 17, 2024. The contract is not designated with any set-aside requirements, indicating open competition....
  • SPE2DB24D2010
    Indefinite Delivery Contract
  • SPE2DB24D2010-SPE2DB25FZUR8
    Delivery Order

The federal contract award is for the delivery of XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML pharmaceutical products to the Defense Logistics Agency (DLA). The contract, valued at $1,369.35, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Firm Fixed Price Delivery Order with a term running through January 23, 2025. This contract award is associated with a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

Generated 4/23/25, 12:49 PM